Table 3.
Association between signature and clinicopathological manifestations.
| Training cohort (N = 333) | P | Validation cohort (N = 166) | P | |||
|---|---|---|---|---|---|---|
| High risk | Low risk | High risk | Low risk | |||
| n = 166 | n = 167 | n = 81 | n = 85 | |||
| Age (%) | ||||||
| ≤60 | 76 (45.8) | 88 (52.7) | 0.207 | 35 (43.2) | 45 (52.9) | 0.210 |
| >60 | 90 (54.2) | 79 (47.3) | 46 (56.8) | 40 (47.1) | ||
| Gender (%) | ||||||
| Female | 46 (27.7) | 41 (24.6) | 0.512 | 26 (32.1) | 20 (23.5) | 0.218 |
| Male | 120 (72.3) | 126 (75.4) | 55 (67.9) | 65 (76.5) | ||
| Smoking (%) | ||||||
| Former and current smoker | 96 (57.8) | 108 (64.7) | 0.200 | 55 (67.9) | 55 (64.7) | 0.663 |
| Nonsmoker | 70 (42.2) | 59 (35.3) | 26 (32.1) | 30 (35.3) | ||
| HPV status (%) | ||||||
| Negative | 24 (14.5) | 29 (17.4) | <0.001 | 12 (14.8) | 14 (16.5) | 0.034 |
| Positive | 1 (0.6) | 22 (13.2) | 1 (1.2) | 14 (16.5) | ||
| Unknown | 141 (84.9) | 116 (69.5) | 68 (84.0) | 62 (72.9) | ||
| Grade (%) | ||||||
| G1-2 | 129 (77.7) | 107 (64.1) | 0.020 | 64 (70.9) | 59 (69.4) | 0.178 |
| G3-4 | 33 (19.9) | 51 (30.5) | 16 (19.8) | 21 (24.7) | ||
| Unknown | 4 (2.4) | 9 (5.4) | 1 (1.2) | 5 (5.9) | ||
| Stage (%) | ||||||
| I | 5 (3.0) | 12 (7.2) | 0.261 | 7 (8.6) | 1 (1.2) | <0.001 |
| II | 20 (12.0) | 25 (15.0) | 10 (12.3) | 14 (16.5) | ||
| III | 33 (19.9) | 23 (13.8) | 13 (16.0) | 9 (10.6) | ||
| IV | 86 (51.8) | 84 (50.3) | 48 (59.3) | 41 (48.2) | ||
| Unknown | 22 (13.3) | 23 (13.8) | 3 (3.7) | 20 (23.5) | ||